Clinical Guidelines Publication

Home / News & Publications / Official Release: Saudi National Guidelines for Urothelial Cancer
Clinical Guidelines Release Official Guideline Release Full Version Available Peer-Reviewed Consensus

Official Release: Saudi National Guidelines for Urothelial Cancer

The multidisciplinary expert steering committee of the Saudi Genitourinary (GU) Working Group has officially published the comprehensive clinical practice guidelines. This evidence-based document provides standardized diagnostic algorithms, risk stratification matrices, and localized systemic sequencing pathways for healthcare providers across Saudi Arabia.
Official Release: Saudi National Guidelines for Urothelial Cancer
Official cover and multidisciplinary framework published by the Saudi GU Working Group committee.

Executive Overview & Clinical Impact

Genitourinary oncologists and urologic surgeons in Saudi Arabia now have direct access to an updated, unified national reference framework. These guidelines synthesize the latest global evidence (including EAU, ESMO, and ASCO consensus) and tailor diagnostic and therapeutic algorithms to the specific healthcare capabilities and formulary pathways of the Kingdom.

Key Chapters & Clinical Modules Included

The full online guideline platform features interactive decision trees, high-resolution diagnostic charts, and evidence grades across each phase of disease:

Module 01

Diagnostic Cystoscopy & TURBT Quality Criteria

Standardized biopsy techniques, detrusor muscle sampling requirements, and photodynamic/narrow-band diagnostic tools.
Module 02

EAU/Saudi Risk Stratification in NMIBC

Differentiating low, intermediate, high, and very-high-risk non-muscle invasive disease with prognostic nomograms.
Module 03

Intravesical BCG Immunotherapy & Chemotherapy

Induction and maintenance schedules, overcoming local BCG shortages, and salvage options for BCG-unresponsive disease.
Module 04

Muscle-Invasive Bladder Cancer (MIBC) Multidisciplinary Care

Neoadjuvant cisplatin-based chemotherapy (NAC), radical cystectomy benchmarks, and trimodality bladder-preservation protocols.
Module 05

Metastatic Urothelial Carcinoma (mUC) Systemic Therapy

New standard-of-care first-line Enfortumab Vedotin plus Pembrolizumab (EV-302), platinum-based regimens, and second-line ADC sequencing.

Access the Complete Interactive Urothelial Cancer Guidelines

Review all 14+ clinical decision algorithms, evidence citations, staging nomograms, and treatment protocols on our specialized guideline platform.

Explore Complete Urothelial Cancer Guidelines →